Here's Why ArQule Shares Rose as Much as 44.7% Today
The stock soared to its highest level in over 10 years on encouraging, early-stage clinical results.
ArQule
ARQL
ARQL
$8.22
$1.92
0.0%
BATS BZX Real Time Price as of June 14, 2019, 3:38 p.m.
View Interactive ARQL Charts
A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.
News & Analysis: ArQule
Stock Market News: Chewy Goes Public; ArQule Soars on Cancer Study
Stocks were poised to ease lower on Friday morning.
Arqule Inc (ARQL) Q1 2019 Earnings Call Transcript
ARQL earnings call for the period ending March 31, 2019.
Here's Why ArQule Rose as Much as 12.7% Today
The oncology-focused pharma announced first-quarter 2019 operating results.
Can Arqule Stock Continue Rocketing Higher?
This biotech recently shot up after an experimental treatment helped one patient beat back leukemia.
Why Rosetta Stone, ArQule, and Fly Leasing Jumped Today
Find out how earnings helped these companies' shares rise.
Arqule Inc (ARQL) Q4 2018 Earnings Conference Call Transcript
ARQL earnings call for the period ending December 31, 2018.
Here's Why ArQule Is Soaring Today
The company reported fourth-quarter and full-year 2018 earnings and guidance for 2019.
ArQule (ARQL) Q3 2018 Earnings Conference Call Transcript
ARQL earnings call for the period ending September 30, 2018.
Here's Why ArQule Inc. Rose as Much as 20.1% Today
The small-cap biopharma announced second-quarter 2018 earnings -- and a surprise profit.
